14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ELMD vs DXR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Daxor Corporation (DXR) captures the overall head-to-head institutional edge over Electromed, Inc. (ELMD) on higher Unified Composite conviction (52.2/100 HOLD vs. 41.1/100 SELL) after splitting the core matrix 5–4 (led by Growth & Scale, Options & Positioning), while ELMD wins 4–2 across the 6-pillar growth and valuation breakdown. ELMD trades at $23.10 (15.6x Forward P/E, 19.4% operating margin) versus DXR at $8.36 (64.5x Forward P/E, -5894.3% operating margin).
Growth vs. Quality Trade-Off: DXR earns the overall head-to-head edge with a stronger Unified Composite Score (52.2/100 HOLD vs. ELMD 41.1/100 SELL) and 0.28β · 32% Vol risk profile, whereas ELMD leads top-line expansion (+10.6% YoY revenue growth, 0.35x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: ELMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.3); meanwhile DXR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ELMD vs DXR. Trailing 12-month operating profitability (ELMD 19.4% vs DXR -5894.3%) and valuation multiples (ELMD 15.6x vs DXR 64.5x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Instruments & Supplies value chain with $49.5M market capitalization and -5894.3% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ELMD vs DXR Key Questions & Quantitative Answers
As of Nov 16, 2026, Daxor Corporation (DXR) captures the overall head-to-head institutional edge over Electromed, Inc. (ELMD) on higher Unified Composite conviction (52.2/100 HOLD vs. 41.1/100 SELL) after splitting the core matrix 5–4 (led by Growth & Scale, Options & Positioning), while ELMD wins 4–2 across the 6-pillar growth and valuation breakdown. ELMD trades at $23.10 (15.6x Forward P/E, 19.4% operating margin) versus DXR at $8.36 (64.5x Forward P/E, -5894.3% operating margin). Growth vs. Quality Trade-Off: DXR earns the overall head-to-head edge with a stronger Unified Composite Score (52.2/100 HOLD vs. ELMD 41.1/100 SELL) and 0.28β · 32% Vol risk profile, whereas ELMD leads top-line expansion (+10.6% YoY revenue growth, 0.35x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ELMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.3); meanwhile DXR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DXR leads the Growth & Scale pillar: ELMD posts +10.6% YoY revenue growth and +28.0% YoY earnings growth on $76M TTM revenue (79.0% gross margin, 19.4% operating margin), compared with DXR at +25.5% YoY revenue growth and +329.3% YoY earnings growth on $31,360 TTM revenue (100.0% gross margin, -5894.3% operating margin). On trailing 12-month operating scale, ELMD generates $76M in USD-normalized revenue versus $31,360 for DXR. In operating R&D and SG&A reinvestment, ELMD deploys 59.6% of Rev ($45M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DXR.
ELMD screens cheaper on headline valuation multiples. ELMD trades at 15.6x Forward P/E, 17.6x Trailing P/E, 0.35x PEG, and 2.6x EV/Revenue (11.4% FCF margin), whereas DXR trades at 64.5x Forward P/E, 7.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ELMD (24.5% ROE) versus DXR (14.2% ROE) capital efficiency.
In options market volatility and institutional positioning, ELMD carries 43.0% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.23x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.76β · 45% Vol realized risk). By comparison, DXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.28β · 32% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.